Table 3.
Treatment response in 37 evaluable relapsed/refractory patients with measurable disease at baseline.
| Response at end of cycle |
||||
|---|---|---|---|---|
| Category |
cycle 1 – 3 |
cycle 4 – 5/6 |
Best Response |
End of treatment* |
| Evaluable | N = 35/37§ | N = 23/37† | N = 37/37 | N = 34/37** |
| N (%) | 35 (100.0%) | 23 (100.0%) | 37 (100.0%) | 34 (100.0%) |
| CR | 5 (14.3%) | 3 (13.0%) | 5 (13.5%)‡ | 3 (8.8%)& |
| PR | 7 (20.0%) | 7 (30.4%) | 10 (27.0%)‡ | 8 (23.5%)& |
| SD | 15 (42.9%) | 6 (26.1%) | 12 (32.4%) | 6 (17.6%) |
| PD | 8 (22.9%) | 7 (30.4%) | 10 (27.0%) | 17 (50.0%) |
CR = Complete response, PR = Partial response, SD = Stable disease/no response, PD = Progressive disease
Best overall response: 40.5% (15/37) (CR 5/37 = 13.5%; 10/37 PR = 27.0%)
End of treatment response: 32.4% (11/34) (CR 3/34 = 8.8%; 8/34 PR = 23.5%)
Last evaluation regardless of time (after 3rd or 5/6th cycle)
Excluded patients 2 pts. with PD before completion of cycle 3
Excluded patients: 11 pts. with PD before completion of cycle 5/6 not included (2 pts. before cycle 3; 8 pts. at mid evaluation 1 pt. after cycle 4) and 3 pts. due to tumor surgery after mid evaluation.
Excluded Patients: 3 pts due to tumor surgery after mid evaluation after cycle 3.